FREMONT, Calif., Sept. 3 ValGenesis, Inc. today announced the worldwide availability of the vDoc360 connector for EMC Documentum v.6.5 to increase enterprise productivity specifically for regulated Pharmaceuticals, Biotech and Medical Devices companies. The vDoc360 seamlessly integrates ValGenesis with the EMC Documentum v.6.5 Server. This integration offers Documentum customers an end-to-end secured, 100% paperless validation lifecycle management solution and central storage of validation documents provided by these two complementary technologies.
This offering will seamlessly provide global access, retrieval and storage of corporate validation data and documents generated by ValGenesis within EMC Documentum v.6.5 Server. This helps to leverage real-time reporting and the robust search functionality of Documentum Server for validation data and documents.
With the vDoc360 connector for EMC Documentum, customers can extend Documentum's access control and audit capabilities to corporate validation data and documents. Furthermore, document management staff can apply federated retention policies to unify management practices across all documents and record types throughout their organizations, ensuring consistent compliance to regulatory requirements.
"Many Life Sciences companies use Documentum for document management and want the flexibility to leverage this investment. ValGenesis continues to offer state-of-the-art ValGenesis software and now allows customers to use Documentum as the central repository for validation data and documents throughout the enterprise with this integration. ValGenesis also interfaces with many other systems, including automated test engines, to leverage the power of these test engines for validation requirements. The interface with Documentum facilitates the storage of the test data and documents generated by test engines in Documentum through configurable workflow provided by ValGenesis. ValGenesis offers Documentum users strengthened return on investment and additional usability, functionality and productivity," said Siva Samy, Ph.D., ValGenesis Chief Product Strategist.
ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies by enabling a 100% paperless validation process. ValGenesis is the first Enterprise application to automate the validation lifecycle and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA) awarded ValGenesis the prestigious New Innovative Technology award.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
For more information, contact: Mike Beaudro, 510-445-0505, [email protected]
SOURCE ValGenesis, Inc.